Literature DB >> 26951321

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial.

Antonio Avallone1, Alfredo Budillon2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26951321     DOI： 10.1200/JCO.2015.66.1512

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.

Authors:  Hung-Chih Hsu; Yu-Chun Liu; Chuang-Wei Wang; Wen-Chi Chou; Yu-Jen Hsu; Jy-Ming Chiang; Yung-Chang Lin; Tsai-Sheng Yang
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

2.  Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer.

Authors:  Li Liang; Mengling Liu; Xun Sun; Yitao Yuan; Ke Peng; Khalid Rashid; Yiyi Yu; Yuehong Cui; Yanjie Chen; Tianshu Liu
Journal:  Cancer Cell Int       Date:  2021-02-25       Impact factor: 5.722
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.